Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment
Authors' conclusion
A therapeutic range of adalimumab trough levels of 9.6 to 13 µg/mL, which corresponds with an optimal clinical effect, was identified.
Study context
- Population
- Children aged < 18 years with noninfectious uveitis (NIU) treated with adalimumab
- Participants
- 36 children
- Exposure
- Adalimumab trough levels in complete responders vs partial or non-responders
- Outcome
- Therapeutic range for adalimumab trough levels
- Follow-up
- At least 24 weeks after start adalimumab
Main finding
As reported in the abstract
Adalimumab trough levels by response
Complete responders
11.8
range 6.9–33.0 · μg/mL
P = 0,004
- ROC AUC
- 0,749 (95% CI, 0,561-0,937)
- Lower margin of therapeutic range (ROC)
- 9.6 µg/mL
- Cut-off sensitivity
- 88%
- Cut-off specificity
- 56%
- Cut-off PPV
- 85%
- Cut-off NPV
- 62.5%
- Upper margin of therapeutic range (concentration effect curve)
- 13 µg/mL
Observational data: associations, not effects.
Further findings
Patients with trough concentration exceeding 13 µg/mL
- Approximately one-third
- 30.5%
Free anti-drug antibodies (ADA)
- Patients with free ADA
- 2 (5.5%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment. Pediatr Rheumatol Online J. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →